<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Baptiste</forename><surname>Hervier</surname></persName>
							<email>baptiste.hervier@psl.aphp.fr</email>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">INSERM U1135</orgName>
								<orgName type="department" key="dep2">Centre d&apos;Immunologie et des Maladies Infectieuses</orgName>
								<orgName type="institution" key="instit1">Sorbonne Universite ´s</orgName>
								<orgName type="institution" key="instit2">Universite ´Pierre et Marie Curie Universite ´Paris 06</orgName>
								<orgName type="institution" key="instit3">CNRS ERL8255</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">DHU I2B</orgName>
								<orgName type="institution" key="instit1">Centre National de Re ´fe ´rence des Maladies Musculaires</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR S974</orgName>
								<orgName type="institution">INSERM</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Universite ´Pierre et Marie Curie</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">De ´partment de Pneumologie</orgName>
								<orgName type="institution" key="instit1">Universite ´Paris 13</orgName>
								<orgName type="institution" key="instit2">Sorbonne Paris Cite ´</orgName>
								<address>
									<postCode>2363</postCode>
									<region>EA</region>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Avicenne</orgName>
								<address>
									<postCode>93000</postCode>
									<settlement>Bobigny</settlement>
									<country>France; ‡ ‡</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="laboratory">Laboratoire de Virologie</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Cochin-La Roche Guyon</orgName>
								<address>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country>France; xx</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<addrLine>Ho ˆpital Cochin-La Roche Guyon</addrLine>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mikae</forename><surname>¨l Perez</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Centre de Recherche des Cordeliers</orgName>
								<orgName type="laboratory">INSERM UMR S1138</orgName>
								<orgName type="institution">Universite Ṕierre et Marie Curie</orgName>
								<address>
									<postCode>75006</postCode>
									<settlement>Paris</settlement>
									<country>France; {</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">De ´partement de Neuropathologie</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country>Germany; ‖</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">De ´partement de Me ´decine Interne et Maladies Syste ´miques</orgName>
								<orgName type="institution" key="instit1">Ho ˆpital du Bocage</orgName>
								<orgName type="institution" key="instit2">Centre Hospitalier Universitaire</orgName>
								<address>
									<postCode>21000</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">INSERM Centre d&apos;Investigation Clinique-Epide ´miologie Clinique</orgName>
								<address>
									<postCode>1432, 2100</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yves</forename><surname>Allenbach</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">DHU I2B</orgName>
								<orgName type="institution" key="instit1">Centre National de Re ´fe ´rence des Maladies Musculaires</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR S974</orgName>
								<orgName type="institution">INSERM</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Universite ´Pierre et Marie Curie</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">De ´partment de Pneumologie</orgName>
								<orgName type="institution" key="instit1">Universite ´Paris 13</orgName>
								<orgName type="institution" key="instit2">Sorbonne Paris Cite ´</orgName>
								<address>
									<postCode>2363</postCode>
									<region>EA</region>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Avicenne</orgName>
								<address>
									<postCode>93000</postCode>
									<settlement>Bobigny</settlement>
									<country>France; ‡ ‡</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="laboratory">Laboratoire de Virologie</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Cochin-La Roche Guyon</orgName>
								<address>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country>France; xx</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<addrLine>Ho ˆpital Cochin-La Roche Guyon</addrLine>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Herve</forename><surname>´devilliers</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fleur</forename><surname>Cohen</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Service de Me ´decine Interne 2</orgName>
								<orgName type="laboratory">Centre National de Re ´fe ´rence des Maladies Auto-immune et Syste ´miques Rares</orgName>
								<orgName type="institution">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country>France; †</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yurdag€</forename><surname>Ul Uzunhan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">DHU I2B</orgName>
								<orgName type="institution" key="instit1">Centre National de Re ´fe ´rence des Maladies Musculaires</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">De ´partment de Pneumologie</orgName>
								<orgName type="institution" key="instit1">Universite ´Paris 13</orgName>
								<orgName type="institution" key="instit2">Sorbonne Paris Cite ´</orgName>
								<address>
									<postCode>2363</postCode>
									<region>EA</region>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Avicenne</orgName>
								<address>
									<postCode>93000</postCode>
									<settlement>Bobigny</settlement>
									<country>France; ‡ ‡</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="laboratory">Laboratoire de Virologie</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Cochin-La Roche Guyon</orgName>
								<address>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country>France; xx</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<addrLine>Ho ˆpital Cochin-La Roche Guyon</addrLine>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hanane</forename><surname>Ouakrim</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">DHU I2B</orgName>
								<orgName type="institution" key="instit1">Centre National de Re ´fe ´rence des Maladies Musculaires</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR S974</orgName>
								<orgName type="institution">INSERM</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Universite ´Pierre et Marie Curie</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Centre de Recherche des Cordeliers</orgName>
								<orgName type="laboratory">INSERM UMR S1138</orgName>
								<orgName type="institution">Universite Ṕierre et Marie Curie</orgName>
								<address>
									<postCode>75006</postCode>
									<settlement>Paris</settlement>
									<country>France; {</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">De ´partement de Neuropathologie</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country>Germany; ‖</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">De ´partement de Me ´decine Interne et Maladies Syste ´miques</orgName>
								<orgName type="institution" key="instit1">Ho ˆpital du Bocage</orgName>
								<orgName type="institution" key="instit2">Centre Hospitalier Universitaire</orgName>
								<address>
									<postCode>21000</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">INSERM Centre d&apos;Investigation Clinique-Epide ´miologie Clinique</orgName>
								<address>
									<postCode>1432, 2100</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">De ´partment de Pneumologie</orgName>
								<orgName type="institution" key="instit1">Universite ´Paris 13</orgName>
								<orgName type="institution" key="instit2">Sorbonne Paris Cite ´</orgName>
								<address>
									<postCode>2363</postCode>
									<region>EA</region>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Avicenne</orgName>
								<address>
									<postCode>93000</postCode>
									<settlement>Bobigny</settlement>
									<country>France; ‡ ‡</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="laboratory">Laboratoire de Virologie</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Cochin-La Roche Guyon</orgName>
								<address>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country>France; xx</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<addrLine>Ho ˆpital Cochin-La Roche Guyon</addrLine>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karim</forename><surname>Dorgham</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">INSERM U1135</orgName>
								<orgName type="department" key="dep2">Centre d&apos;Immunologie et des Maladies Infectieuses</orgName>
								<orgName type="institution" key="instit1">Sorbonne Universite ´s</orgName>
								<orgName type="institution" key="instit2">Universite ´Pierre et Marie Curie Universite ´Paris 06</orgName>
								<orgName type="institution" key="instit3">CNRS ERL8255</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR S974</orgName>
								<orgName type="institution">INSERM</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Universite ´Pierre et Marie Curie</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jean-Franc ¸ois</forename><surname>Me</surname></persName>
						</author>
						<author>
							<persName><roleName>{{</roleName><forename type="first">Elisabeth</forename><surname>Longchampt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Stenzel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Isabelle</forename><surname>Cremer</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Centre de Recherche des Cordeliers</orgName>
								<orgName type="laboratory">INSERM UMR S1138</orgName>
								<orgName type="institution">Universite Ṕierre et Marie Curie</orgName>
								<address>
									<postCode>75006</postCode>
									<settlement>Paris</settlement>
									<country>France; {</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">De ´partement de Neuropathologie</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country>Germany; ‖</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">De ´partement de Me ´decine Interne et Maladies Syste ´miques</orgName>
								<orgName type="institution" key="instit1">Ho ˆpital du Bocage</orgName>
								<orgName type="institution" key="instit2">Centre Hospitalier Universitaire</orgName>
								<address>
									<postCode>21000</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">INSERM Centre d&apos;Investigation Clinique-Epide ´miologie Clinique</orgName>
								<address>
									<postCode>1432, 2100</postCode>
									<settlement>Dijon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Benveniste</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">DHU I2B</orgName>
								<orgName type="institution" key="instit1">Centre National de Re ´fe ´rence des Maladies Musculaires</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Pitie ´-Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">UMR S974</orgName>
								<orgName type="institution">INSERM</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Universite ´Pierre et Marie Curie</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">De ´partment de Pneumologie</orgName>
								<orgName type="institution" key="instit1">Universite ´Paris 13</orgName>
								<orgName type="institution" key="instit2">Sorbonne Paris Cite ´</orgName>
								<address>
									<postCode>2363</postCode>
									<region>EA</region>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Avicenne</orgName>
								<address>
									<postCode>93000</postCode>
									<settlement>Bobigny</settlement>
									<country>France; ‡ ‡</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="laboratory">Laboratoire de Virologie</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Cochin-La Roche Guyon</orgName>
								<address>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country>France; xx</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">Assistance Publique-Ho ˆpitaux de Paris</orgName>
								<address>
									<addrLine>Ho ˆpital Cochin-La Roche Guyon</addrLine>
									<postCode>75014</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vincent</forename><surname>Vieillard</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">INSERM U1135</orgName>
								<orgName type="department" key="dep2">Centre d&apos;Immunologie et des Maladies Infectieuses</orgName>
								<orgName type="institution" key="instit1">Sorbonne Universite ´s</orgName>
								<orgName type="institution" key="instit2">Universite ´Pierre et Marie Curie Universite ´Paris 06</orgName>
								<orgName type="institution" key="instit3">CNRS ERL8255</orgName>
								<address>
									<postCode>75013</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">The American Association of Immunologists, Inc</orgName>
								<address>
									<addrLine>Suite 650</addrLine>
									<postCode>1451, 20852</postCode>
									<settlement>Rockville Pike, Rockville</settlement>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">{{ De ´partement d&apos;Anatomopathologie</orgName>
								<orgName type="institution">Ho ˆpital Foch</orgName>
								<address>
									<postCode>92073</postCode>
									<settlement>Suresnes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">CNRS</orgName>
								<orgName type="institution" key="instit2">Universite Ṕierre et Marie Curie</orgName>
								<address>
									<settlement>Paris</settlement>
									<region>H.D., F</region>
									<country>France. B.H</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">De ´partement de Me ´decine Interne et Immunologie Clinique</orgName>
								<orgName type="institution">Ho ˆpital de la Pitie ´-Salpe ˆtrie `re</orgName>
								<address>
									<addrLine>47-83 Boulevard de l&apos;Ho ˆpital</addrLine>
									<postCode>75651</postCode>
									<settlement>Paris Cedex 13</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome</title>
					</analytic>
					<monogr>
						<idno type="ISSN">0022-1767</idno>
					</monogr>
					<idno type="MD5">CFEB050835FA34AD26E6D196DFC2BBC6</idno>
					<idno type="DOI">10.4049/jimmunol.1501902</idno>
					<note type="submission">Received for publication August 26, 2015. Accepted for publication June 29, 2016.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>0000-0002-1388-1121 (B.H.)</term>
					<term>0000-0002-0607-5519 (M.P.)</term>
					<term>0000-0003-3262-8647 (H.O.)</term>
					<term>0000-0001-9539-3203 (K.D.)</term>
					<term>0000-0002-8942-6977 (J.-F.M.) C., Y.U., I.C., W.S., O.B., and V.V. designed the study</term>
					<term>B.H., Y.A., F.C., Y.U., and O.B. followed the patients</term>
					<term>all authors were involved in acquiring and interpreting the data</term>
					<term>B.H. and V.V. performed the phenotype and functional NK cell analyses</term>
					<term>M.P., Y.A., H.O., E.L., W.S., and I.C. performed the histological studies</term>
					<term>K.D. performed flow cytometry and molecular biology analyses</term>
					<term>J.-F.M. performed the cytokine titrations</term>
					<term>B.H. and H.D. performed the statistical analyses</term>
					<term>aSS, antisynthetase syndrome</term>
					<term>DC, dendritic cell</term>
					<term>ILD, interstitial lung disease</term>
					<term>ILT2, Ig-like transcript 2</term>
					<term>qPCR, quantitative PCR</term>
					<term>ROC, receiver operating characteristic</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Antisynthetase syndrome (aSS) is characterized by the association of interstitial lung disease and myositis with anti-tRNA synthetase autoantibodies.</s><s>Immune mechanisms leading to aSS could be initiated in the lungs, but the role of NK cells has not yet been studied.</s><s>Both extensive NK cell phenotype and functions were compared between 33 patients and 26 controls.</s><s>Direct and redirected polyfunctionality assays (degranulation and intracellular production of TNF-a and IFN-g) were performed spontaneously or after IL-12 plus IL-18 stimulation in the presence of K562 or P815 target cells, respectively.</s><s>NK cells from inactive patients showed normal phenotype, whereas active aSS revealed a differentiated NK cell profile, as indicated by increased CD57 and Ig-like transcript 2 and an inability to produce IFN-g (p = 0.002) compared with controls.</s><s>Importantly, active aSS was more specifically associated with a significant NKp30 decrease (p = 0.009), although levels of mRNA and intracellular protein were similar in aSS and healthy controls.</s><s>This NKp30 decrease was strongly correlated with reduced NK cell polyfunctionality in both direct and redirected killing assays with anti-NKp30 Abs (p = 0.009 and p = 0.03, respectively), confirming its important impact in aSS.</s><s>Histological studies revealed massive infiltrations of NK cells inside the lungs of aSS patients (148 versus 11/mm 2 ).</s><s>Taken together, these data suggest that NK cells and NKp30 could play a role in aSS pathogenesis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>A ntisynthetase syndrome (aSS) is an autoimmune disease characterized by the presence of autoantibodies directed against different aminoacyl-tRNA synthetases, of which hystidyl-tRNA synthetase (Jo-1) is the most common target <ref type="bibr" target="#b0">(1)</ref>.</s><s>The aSS spectrum mainly consists of interstitial lung disease (ILD) and inflammatory myopathy <ref type="bibr" target="#b1">(2,</ref><ref type="bibr" target="#b2">3)</ref>.</s><s>The prognosis of aSS is closely linked to ILD, which can progress to severe lung fibrosis and pulmonary hypertension (4), even with the use of immunosuppressive drugs <ref type="bibr" target="#b4">(5)</ref>.</s><s>Although aSS pathogenesis remains largely unknown, there is increasing evidence of an involvement of both innate and adaptive immunity: the disease could start in the lungs, where Jo-1 is expressed in a specific structural conformation <ref type="bibr" target="#b5">(6)</ref>.</s><s>Under the influence of proteolytic enzymes (granzymes), Jo-1 is cleaved and becomes immunogenic <ref type="bibr" target="#b6">(7)</ref>.</s><s>Mouse models have demonstrated that a Jo-1 peptide induces the activation of innate immune cells through the signaling pathways of both TLR2 and TLR4 <ref type="bibr" target="#b7">(8)</ref>.</s><s>Furthermore, these Jo-1 peptides act as chemoattractants, inducing the migration of immune cells into the lung and the production of specific autoantibodies <ref type="bibr" target="#b6">(7)</ref>.</s><s>To date, however, the specific contribution of NK cells to the aSS pathogenesis has not been studied.</s></p><p><s>It has generally been assumed that NK cells provide surveillance in the early defense against viruses and tumor cells <ref type="bibr" target="#b8">(9)</ref>.</s><s>Heterogeneous subsets of NK cells differ in their proliferative potential, homing characteristics, and functional properties.</s><s>They can be divided into two major subsets, based on the density of CD56 cell surface expression.</s><s>Both subsets play relatively distinct and important roles in the immune response <ref type="bibr" target="#b9">(10)</ref>.</s><s>CD56 dim NK cells are present in the periphery and produce relatively low levels of cytokine but can spontaneously lyse susceptible target cells through the perforin/granzyme pathways.</s><s>Conversely, CD56 bright NK cells <ref type="bibr" target="#b10">(11)</ref> produce a wide range of cytokines (including IFN-g and TNF-a) and chemokines, but their ability to kill target cells spontaneously is weak <ref type="bibr" target="#b10">(11)</ref>.</s></p><p><s>The activity of NK cells is controlled by a dynamic signal balance between a vast network of activating and inhibitory receptors, which are triggered upon interaction with their cognate ligands to detect their cellular targets while sparing normal cells <ref type="bibr" target="#b8">(9)</ref>.</s><s>Under normal circumstances NK cells express inhibitory receptors, such as killer cell Ig-like receptors, Ig-like transcript 2 (ILT2/CD85j), and CD94/NKG2A receptors, which recognize some self-molecules of the HLA-I repertoire, constitutively expressed on host cells.</s><s>NK cells will only mount an efficient response when signaling exceeds a critical threshold, specifically when receptor activation exceeds the counterbalancing influence of inhibitory receptors.</s><s>These activating receptors include NKG2D, FCgRIIIA (CD16a), and the natural cytotoxic receptors NKp46 and NKp30.</s></p><p><s>The aim of this study is to provide the first extensive phenotypic and functional characterization of NK cells in patients with aSS.</s><s>This study therefore focused on circulating NK cells from peripheral blood as well as NK cell infiltrates within the lung and muscle target tissues to establish their involvement in the aSS pathogenesis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and controls</head><p><s>This study was approved by the hospital Ethics Committee (CPP-IDF-VI, June 26, 2012) and was conducted in accordance with French law; anonymously reported patients gave their consent.</s><s>Thirty-three patients were included between 2012 and 2016.</s><s>All patients were diagnosed with aSS based on the following association of clinical manifestations: myositis, ILD, and/or rheumatic symptoms and serologic features (two consecutive positive tests for aminoacyl-tRNA synthetases [Luminex, Austin, TX] and immunodot assays [Euroimmun, L€ ubeck, Germany]).</s><s>Patients (6 men/ 27 women; median age, 48 y; age range, 19-77 y) were divided into inactive and active groups (Table <ref type="table" target="#tab_0">I</ref>).</s><s>They were classified as active in case of 1) active myositis (myalgia or muscle weakness and creatine kinase level higher than twice the normal range), 2) arthritis (slight pain and swollen joints), and/or 3) appearance or deterioration of interstitial lung disease (.10% decrease in lung vital capacity or .15%</s><s>decrease in CO lung diffusion capacity).</s><s>At inclusion, specific treatments were as low as possible and prescribed at a stable dose for at least 1 mo.</s><s>As shown in Table <ref type="table" target="#tab_0">I</ref>, there were neither demographic (median age, 51 versus 47 y, p = 0.91) nor therapeutic differences between active (n = 13) and inactive (n = 20) aSS patients (the number of steroid-free patients was similar in both groups [4 of 20 versus 6 of 13, p = 0.14], as was the median dose of steroids [5.5 versus 2.5 mg/d, p = 0.52]).</s><s>Phenotyping analyses of NK cells from patients with aSS were compared with 26 healthy controls (21 women, 5 men, aged between 22 and 58 y), whereas NK cell functional analyses as well as serum cytokine measurements were compared with 10 other controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometry analyses</head><p><s>Nine-color flow cytometry analyses (Gallios, Beckman Coulter) were performed on freshly isolated blood cells.</s><s>NK cells were analyzed after staining with the appropriate Ab cocktails (Supplemental Table <ref type="table" target="#tab_0">I</ref>).</s><s>At least 20,000 lymphocytes were recorded and data were analyzed using FlowJo software version 10 (Tree Star).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NK cell degranulation assays and cellular production of cytokines</head><p><s>Polyfunctionality assays simultaneously detected degranulation assays and intracellular production of TNF-a and IFN-g <ref type="bibr" target="#b11">(12)</ref>.</s><s>Direct killing assays, as well as cross-linking assays, were performed using K562 target cells with and without anti-NKp30 mAb (R&amp;D Systems) or a mouse IgG2a isotype control (R&amp;D Systems) coated at 2.5 mg/ml onto flat-bottom 96-well MaxiSorp plates (Nunc) <ref type="bibr" target="#b12">(13)</ref>.</s><s>Redirected killing assays were performed in similar conditions, with P815 target cells.</s><s>Freshly isolated PBMCs were incubated overnight with and without IL-12 (10 ng/ml) and IL-18 (100 ng/ml) (R&amp;D Systems) to stimulate cytokine production.</s><s>To test the pathogenic role of anti-Jo-1 autoantibodies, PBMCs were incubated with IgG purified from two active patients' sera (1 mg/ml) and one healthy donor, as a control, using a Melon gel IgG purification kit (Pierce) and buffer was exchanged using Amicon Ultra 30,000 normal molecular weight limit centrifugal filters (Merck Millipore).</s><s>Data were analyzed with FlowJo, and the fraction of NK cells that were positive for up to three functions was defined using the software's Boolean gate algorithm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum cytokine assays</head><p><s>Serum samples from patients and healthy controls were processed immediately after being collected and stored at 280˚C.</s><s>IFN-g was quantified in duplicate using human IFN-g, IL-2, and IL-15 Quantikine ELISA kits (R&amp;D Systems), and the IFN-a concentration was determined using an antiviral IFN-a cytopathic bioassay <ref type="bibr" target="#b13">(14)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relative NCR3 mRNA quantification</head><p><s>Total RNA was extracted from 200,000 CD3 2 CD56 + -sorted NK cells (S3e cell sorter; Bio-Rad) with TRIzol reagent (Ambion/Life Technologies) and quantified using the NanoVue Plus spectrophotometer (GE Healthcare).</s><s>First-strand cDNA was synthesized using SuperScript IV reverse transcriptase (Invitrogen) with both random hexamers and deoxythymidine nucleotide as primers.</s><s>Real-time quantitative PCR (qPCR) assays were performed in duplicate in a 20-ml reaction mixture, with 25 ng of cDNA as a template using TaqMan gene expression assays (Applied Biosystems) to specifically detect human ACTB (Hs99999903_m1) and NKp30/NCR3 (Hs01553309_g1) transcripts.</s><s>qPCR reactions were run on an ABI 7300 real-time PCR system (Applied Biosystems), according to the manufacturer's instructions, and analyzed with the sequence detection software SDS version 1.1 (Applied Biosystems).</s><s>For each cDNA sample, relative transcript quantities were calculated as DCT values with ACTB as the endogenous gene reference.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Paraffin-embedded explanted lung samples were retrieved from three other patients with severe and end-stage aSS-related usual interstitial pneumonia: two women and one man, 50-55 y old, with anti-Jo-1 (n = 2) or anti-PL12 (n = 1) autoantibodies and with a disease duration ranging from 2 to 9 y.</s><s>These pathological studies were compared with lung biopsies from three controls.</s><s>Serial 7-mm tissue sections were deparaffinized, rehydrated, and pretreated in 10 mM Tris/1 mM EDTA buffer (pH 9) for Ag retrieval and then treated to visualize the appropriate markers <ref type="bibr" target="#b14">(15)</ref>.</s></p><p><s>Frozen muscle biopsies of five independent patients with an aSS-related myositis were also studied in parallel.</s><s>Cryostat-cut sections (7 mm) were stained with H&amp;E <ref type="bibr" target="#b15">(16)</ref>.</s></p><p><s>The immunohistochemical demonstration of NK cells in lungs and muscles was performed using anti-NKp46 mAb (clone 195314; R&amp;D Systems) <ref type="bibr" target="#b14">(15,</ref><ref type="bibr" target="#b16">17)</ref>.</s><s>The characterization of both T and B cells was performed using anti-CD3 and anti-CD20 mAbs (clones F7.2.38 and L26, respectively; Dako) or CD79a mAbs (clone JCB117; Dako).</s></p><p><s>Granzyme B expression in lung NK cells was shown by an NKp46 plus granzyme B double staining, using anti-NKp46 and anti-granzyme B (clone GrB-7; Dako).</s><s>Similarly, myeloid dendritic cells (DCs) were stained by anti-CD3 plus anti-DC-LAMP mAbs (clone 1010E1.01;</s><s>Dendritics), as previously described <ref type="bibr" target="#b17">(18)</ref>.</s></p><p><s>In all cases, appropriate biotinylated secondary Abs were coupled with streptavidin-peroxidase and the peroxidase activity was revealed using either 3-amino-9-ethylcarbazole substrate (lung) and/or 3,39-diaminobenzidine (lung, muscles).</s><s>NK cell count was performed using NDP view 2 (Hamamatsu).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>The quantitative data were described as median values.</s><s>The nonparametric Mann-Whitney U, Kruskal-Wallis, and Wilcoxon tests were used appropriately for comparison of continuous variables between groups.</s><s>Correlations between variables were calculated using the nonparametric Spearman rank-order test.</s><s>Principal component analysis was used to graphically assess the separation between active and inactive patients, with regards to the following variables: CD69, CD57, ILT2, NKp30, and the NK cell functions.</s><s>A logistic model was built to predict the probability of having an active disease.</s><s>For each value of the prediction equation, defined by a combination of the variables of interest (i.e., NKp30, CD57, and ILT2), sensitivity and specificity were calculated and represented by a receiver operating characteristic (ROC) curve.</s><s>A p value ,0.05 was considered significant.</s><s>Analyses were performed using SAS (version 9.3; SAS Institute) or Prism (version 5.0; GraphPad Software).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phenotypic repertoire of NK cells from aSS patients</head><p><s>The percentages and the absolute count of circulating CD3 2 CD56 + NK cells remained similar in patients with active aSS (13%, <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref>) or inactive aSS (14%, ), and controls (9% <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>) (Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>The percentages of CD56 bright and CD56 dim NK cell subsets were equivalent in aSS and healthy donors (Fig. <ref type="figure" target="#fig_0">1B</ref>).</s></p><p><s>To better characterize NK cells from aSS patients, we performed an extensive analysis of cell surface receptors.</s><s>CD56 + NK cells from patients with aSS were indistinguishable from those of the healthy controls, in terms of cell surface expression of a large panel of NK receptors, including cell activation CD69, HLA-DR, and NKp44, and also CD16/FCgRIIIA, CD8a, NKG2D, killer cell Ig-related receptors, NKG2A, NKG2C, as well as the chemokine receptors CX3CR1 and CCR7 (Fig. <ref type="figure" target="#fig_0">1C</ref> and data not shown).</s><s>Additionally, the CD62-L expression was similar in patients and controls <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref>.</s><s>In contrast, NK cells from active aSS patients expressed lower levels of NKp30 compared with both controls (59  versus 81% [45-98], p = 0.006; Fig. <ref type="figure" target="#fig_0">1C</ref>) and inactive patients (90% , p = 0.009).</s><s>Of note, in patients tested twice longitudinally (n = 6), the variation of NKp30 persisted over time (3-6 mo) despite treatment modulations (68%, p = 0.53).</s><s>ILT2/CD85j was also specifically and significantly increased in active aSS patients as compared with controls (63  versus 41% , p = 0.02) and inactive patients (40% [10-83], p = 0.04).</s><s>CD57, another receptor associated with NK cell differentiation, was modulated in active aSS patients versus controls and inactive patients (55  versus 47% , p = 0.02 and 37% , p = 0.03, respectively).</s></p><p><s>Importantly, the percentage of NK cells expressing NKp30 in aSS patients was inversely correlated with both CD57 (r = 20.60;</s><s>p = 0.002) and ILT2 (r = 20.39;</s><s>p = 0.025) (Fig. <ref type="figure" target="#fig_0">1D</ref>).</s><s>These data were strengthened by the calculation of a prediction equation combining the CD57, ILT2, and NKp30 variables and are represented as an ROC curve, which showed significant diagnosis accuracy in predicting the aSS activity (area under the curve = 0.77 compared with 0.5, p = 0.01) (Fig. <ref type="figure" target="#fig_0">1E</ref>).</s></p><p><s>Collectively, these findings suggest that NK cells from aSS patients are more differentiated than are those from healthy donors.</s><s>Importantly, the decreased NKp30 expression is more pronounced in patients with active aSS compared with inactive aSS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NK cell functions of aSS patients</head><p><s>To determine the functional significance of these findings, we further examined the overall functional ability of NK cells of aSS patients: the cytolytic activity of NK cells is mediated by death receptor activation as well as by the release from cytotoxic granules of perforin together with granzymes A and B, which are specifically involved in aSS pathogenesis <ref type="bibr" target="#b5">(6)</ref>.</s></p><p><s>The percentages of NK cells expressing granzyme A, and to a lesser extent granzyme B, were significantly higher in aSS patients (n = 17) as compared with the controls (n = 13) (98 [89299] versus 92% [78293], p = 0.001, and 89 [70299] versus 76% [65294], p = 0.007, respectively).</s><s>The percentage of granulysin + NK cells The Journal of Immunology was also higher in aSS patients than in controls (Supplemental Fig. <ref type="figure" target="#fig_0">1</ref>), whereas the proportion of NK cells expressing intracellular perforin was equivalent in all samples.</s></p><p><s>To obtain further insight into NK cell functions, the degranulation capacity of NK cells was assessed in the presence of K562 target cells; although slightly decreased in active aSS patients, the  In contrast, NK cells from patients with active and inactive aSS displayed a significant decrease in their capacity to produce IFN-g following overnight stimulation with IL-12 and IL-18.</s><s>When compared with healthy controls, active aSS patients showed a dramatic decrease in IFN-g production both spontaneously (2 <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> versus 18% , p = 0.0017) and in the presence of K562 target cells (7% <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> versus 36% , p , 0.001) (Fig. <ref type="figure" target="#fig_1">2B</ref>).</s><s>However, the intracellular production of TNF-a was similar in inactive and active aSS patients as well as in healthy controls, regardless of the culture conditions (Fig. <ref type="figure" target="#fig_1">2B</ref>).</s></p><p><s>Note that serum concentrations of IFN-g, IFN-a, and IL-2 titers were below their detection thresholds in all patients and controls.</s><s>IL-15 serum concentration was similar in controls and aSS patients.</s></p><p><s>These data were then confirmed by a polyfunctionality analysis in which NK cells from the different samples were investigated for multiple functional responses in the presence of K562 target cells.</s><s>NK cells from aSS patients are less polyfunctional than those of healthy donors (Fig. <ref type="figure" target="#fig_1">2C</ref>): the percentage of fully functional NK cells capable of performing three functions (degranulation and production of both IFN-g and TNF-a) was significantly decreased in aSS patients as compared with controls (1% [0.1-5] versus 12% <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref>, p = 0.003).</s><s>In the absence of stimulation, this effect was only significant for NK cells from active aSS patients, whereas after an overnight stimulation with IL-12 and IL-18, a decrease in polyfunctional activity was observed both in inactive and active aSS patients, but more significantly in active aSS patients (Fig. <ref type="figure" target="#fig_1">2C</ref>).</s></p><p><s>NK cells from aSS patients have abnormal functions, which correlate with the disease activity: IFN-g production is dramatically impaired, whereas proteolytic enzymes and their degranulation remain unchanged.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional correlations with NKp30 in aSS patients</head><p><s>Our extensive phenotypic study of NK cells from aSS patients reveals a significant decrease in NKp30 frequency on the NK cell surface of aSS patients, which correlates with their maturation state.</s><s>As shown in Fig. <ref type="figure" target="#fig_2">3A</ref>, the frequency of NKp30 + NK cells is strongly correlated with NK cell degranulation and IFN-g production obtained spontaneously or after overnight stimulation with IL-12 and IL-18.</s><s>Similar data were obtained both in the absence and presence of K562 target cells (Fig. <ref type="figure" target="#fig_2">3A</ref>).</s></p><p><s>The principal component analysis graphically confirmed that NKp30 was associated with the different functional parameters (degranulation and cytokine productions) (Fig. <ref type="figure" target="#fig_2">3B</ref>).</s><s>Furthermore, the other cell surface markers (CD69, ILT2, and CD57) that are modulated in aSS patients clustered together, suggesting that they are closely linked.</s><s>According to these different variables, this multivariate analysis also showed that active and inactive aSS patients form a relatively distinct group (Fig. <ref type="figure" target="#fig_2">3B</ref>).</s></p><p><s>These data were reinforced by cross-linking assays performed in the presence of coated activating anti-NKp30 Abs: IFN-g-producing NK cells were significantly decreased in aSS patients as compared with the controls (2 [0.7-5] versus 9% <ref type="bibr">[3.5-15]</ref>, p = 0.03) after overnight stimulation with IL-12 and IL-18.</s></p><p><s>To better assess the functional role of NKp30 in modulating NK cell functions in aSS, redirected killing assays were also performed with P815 target cells with and without activating anti-NKp30 Abs.</s><s>Fig. <ref type="figure" target="#fig_2">3C</ref> shows that the induction of NK cell polyfunctionality by anti-NKp30 Abs was significantly decreased in aSS patients as compared with the controls.</s><s>This was mainly due to a significant decrease of IFN-g-producing NK cells following overnight stimulation with IL-12 and IL-18 in aSS patients as compared with healthy controls <ref type="bibr">(6 [1.5-9]</ref> versus 16% <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>, p = 0.02).</s><s>As a control, a similar level of IFN-g was observed in the presence of mouse IgG2a isotype control <ref type="bibr">(3 [0.3-12]</ref> versus 7% <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>, p = 0.71).</s></p><p><s>In aSS, modulations of NK cell functions are clearly linked to abnormal NKp30 expression.</s></p><p><s>To further understand the mechanisms of NKp30 cell surface decrease, we quantified by qPCR the relative NKp30 mRNA in purified NK cells from patients (n = 6) and controls (n = 3).</s><s>Fig. <ref type="figure" target="#fig_3">4A</ref>    NK cells after 12-h cultures with medium alone or treated with purified IgG from anti-Jo-1 + patient sera (Jo-1 Ab) or purified IgG from controls (HD IgG).</s><s>Experiments were performed in three controls, five inactive patients, and two active aSS patients.</s><s>(E) Polyfunctional assays of resting or anti-Jo-1-stimulated NK cells from three controls, five inactive patients, and two active aSS patients.</s><s>Assays were performed in the presence of K562 target cells.</s><s>The mean values were analyzed with a Boolean gate algorithm (FlowJo; Tree Star).</s><s>Pie and arc charts were generated using SPICE software (National Institute of Allergy and Infectious Diseases freeware).</s><s>Pies represent the frequency of NK cells positive for up to three responses (to CD107a, IFN-g, and TNF-a).</s><s>Arcs depict the frequency of positive cells for CD107a, IFN-g, and TNF-a.</s><s>None of the results was statistically significant.</s></p><p><s>showed no difference between controls and patients, regardless of the cell surface level of NKp30.</s><s>We then compared cell surface and intracellular levels of NKp30 expression in eight patients and three controls.</s><s>The proportion of NKp30 + NK cells after permeabilization was very high (98% [96-100]) in all samples, irrespective of the NKp30 cell surface expression (Fig. <ref type="figure" target="#fig_3">4B, 4C</ref>).</s><s>These combined result suggest that a decreased in NKp30 surface expression could be associated with posttraductional events.</s><s>We therefore studied the putative role of anti-Jo-1 autoantibodies in the modulation of NKp30 expression.</s><s>The decrease in cell surface NKp30 levels is not associated with a pathogenic role of anti-Jo-1 autoantibodies: in the presence of anti-Jo-1 aSS-specific autoantibodies, the percentage of NKp30 + NK cells remains similar after 12-h in vitro cultures of PBMCs (Fig. <ref type="figure" target="#fig_3">4D</ref>).</s><s>Autoantibody-stimulated and unstimulated PBMCs from aSS patients expressed similar levels of NKp30 (82 [53-96] versus 76% [56-94], p = 0.11), as did the controls (94 [78-96] versus 92% [77-97], p = 0.75).</s><s>Of note, anti-Jo-1 autoantibodies had no effect on NK cel polyfunctionality (Fig. <ref type="figure" target="#fig_3">4E</ref>) or on CD14 + monocyte activation (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NK cell infiltration of the target tissues</head><p><s>In addition to the study of circulating NK cells, immunohistological analyses in target tissues were also performed.</s><s>As expected, the histological analyses of different muscle biopsy specimens showed myopathic changes, including predominant perifascicular atrophy as well as inflammatory infiltrates within both the perimysium and endomysium.</s><s>Based on immunohistochemistry analyses, cells infiltrating the endomysium were distributed as follows: CD3 + T cells .</s><s>CD79a + B cells.</s><s>Interestingly, the presence of rare NK cells (1.1/mm 2 [0-1.5]),</s><s>which represented ,2% of the total immune cells, was observed both in proximity to the myofibers and within the perimysial cellular infiltrate (Supplemental Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p><p><s>Histological features of aSS patient lungs were consistent with severe and diffuse fibrotic lesions, characteristic of usual interstitial pneumonia.</s><s>Cellular infiltrates were intense and diffuse, especially in the most fibrotic zones.</s><s>The characterization of the lymphoid cells by immunohistochemistry showed the presence of CD3 + T cells and CD20 + B cells.</s><s>Importantly, very high and significantly increased numbers of NK cells were observed in the lungs of aSS patients as compared with the controls (148/mm 2 [0-1.5]</s><s>versus 11/mm 2 <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>, Fig. <ref type="figure" target="#fig_4">5E</ref>).</s><s>CD3 + T cells, CD20 + B cells, and DC-LAMP + DCs are grouped in tertiary lymphoid structures, whereas NK cells were distributed throughout the areas showing fibrosis (Fig. <ref type="figure" target="#fig_4">5B-D</ref>, Supplemental Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>Importantly, in lung biopsies NKp46 + NK cells were positive for granzyme B (Fig. <ref type="figure" target="#fig_4">5F</ref>).</s></p><p><s>Taken together, the presence of NK cells in target tissue suggests their involvement in aSS pathogenesis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>With the exception of aSS, involvement of NK cells has been observed in various inflammatory and autoimmune diseases <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref>, including those characterized by pulmonary manifestations <ref type="bibr" target="#b23">(24)</ref>.</s><s>Importantly, note that NK cells have been attributed both a harmful and a beneficial role <ref type="bibr" target="#b20">(21,</ref><ref type="bibr" target="#b23">24)</ref>.</s></p><p><s>By extensively studying blood and tissue NK cells in aSS patients, the present study suggests that these innate immune cells could play a role in the aSS pathogenesis.</s><s>Indeed, the current staining of target tissue sections revealed, to our knowledge for the first time <ref type="bibr" target="#b16">(17)</ref>, the presence of rare NK cells in the muscles and, more importantly, a massive infiltration of NK cells inside the lungs of aSS patients.</s></p><p><s>Among the large panel of NK cell markers that were studied, our in-depth analysis reveals that the natural cytotoxicity-activating NKp30 NK cell receptor is the main circulating NK cell surface receptor involved in aSS: cell surface NKp30 expression was dramatically decreased and specifically associated with aSS activity.</s><s>NKp30 was strongly correlated with a loss of NK cell function and more specifically with a decrease in IFN-g production, especially after the gold standard IL-12 plus IL-18 stimulation.</s><s>Collectively, these data indicate that peripheral blood NK cells could play an inhibitory role in the disease.</s></p><p><s>With regard to NKp30 expression, our data are therefore consistent with those previously reported in a small series of patients with systemic sclerosis <ref type="bibr" target="#b23">(24)</ref>, another autoimmune disease also characterized by interstitial lung disease, a manifestation shared with aSS.</s></p><p><s>The mechanisms leading to cell surface NKp30 decrease remain unclear.</s><s>However, regardless of the phenotypic and functional direct and redirected killing assays, the data from aSS patients are consistent with a dramatic downmodulation of NKp30 expression rather than qualitative abnormalities <ref type="bibr" target="#b24">(25)</ref>.</s><s>NKp30 mRNA and intracellular levels of NKp30 within NK cells are similar in aSS patients and controls, which clearly suggests that NKp30 modulations could be associated with posttraductional events.</s><s>Because we demonstrated that anti-Jo-1 autoantibodies had no impact on NKp30 modulation in vitro, we hypothesize that the mechanisms leading to NKp30 decrease take place prior to autoantibody production.</s><s>However, no danger signal has been identified yet.</s><s>Thus, NKp30 downmodulation was not related to a systemic effect of proinflammatory cytokines, such as IL-2 and IL-15 or type I IFN.</s></p><p><s>NKp30 represents a surrogate marker for NK cell functions in humans <ref type="bibr" target="#b25">(26)</ref> and is involved to a significant extent in both DC killing and maturation <ref type="bibr" target="#b26">(27,</ref><ref type="bibr" target="#b27">28)</ref>.</s><s>DCs are in turn involved in the reciprocal activation of NK cells <ref type="bibr" target="#b28">(29)</ref>, which also implies IL-12 plus IL-18 signaling pathways.</s><s>That DCs and NK cells are not confined to the lungs in aSS patients suggests that NK cell-DC cross-talk could be at play in secondary lymphoid organs, rather than in target tissues.</s><s>However, the significant phenotypic and functional changes of blood NK cells reported in the present study are consistent with the modulation of NK cell differentiation, previously described in humans <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref><ref type="bibr" target="#b31">(32)</ref>: NK cells from active aSS patients displayed a differentiated phenotype with low levels of NKp30, associated with high expressions of CD57 and ILT2.</s><s>These results are further supported by the accuracy of the equation combining these three variables in predicting the activity of aSS.</s></p><p><s>Although peripheral blood NK cells from active aSS harbor an inhibitory regulatory phenotype, their terminal differentiation status is also consistent with their inability to efficiently produce IFN-g and their strong capacity to express proteolytic enzymes, including granzymes A and B, as previously described <ref type="bibr" target="#b18">(19)</ref>.</s><s>Furthermore, such differentiated NK cells, which are massively present in the lung, could thus play a role in directly promoting the aSS in the target tissues.</s><s>Importantly, immune events occurring in the lung have been shown to be the primary trigger of aSS <ref type="bibr" target="#b6">(7)</ref>: it has been hypothesized that the cleavage of the Jo-1 by granzyme B, a serine protease, could recruit and stimulate immune cells, such as monocyte/DC lineage cells <ref type="bibr" target="#b7">(8)</ref>.</s><s>We show in the present study that NK cells positive for granzyme B are more prevalent in peripheral blood and present in the lungs of patients.</s><s>It is therefore possible that functional blood NK cells invade the lungs of aSS patients, both initiating and sustaining the disease, in which the autoantibody production persists over time <ref type="bibr" target="#b32">(33)</ref>.</s><s>Overall, these results strongly suggest that NK cells and their differentiation process could play a key role in the development and/or progression of aSS.</s></p><p><s>Additionally, the diffuse infiltration of NK cells within the lung is also consistent with a specific involvement of NK cells in the lung fibrosis.</s><s>Note that the presence of NK cells in the explanted lungs of aSS patients with a long and refractory disease history despite immunosuppressive treatments suggested a persistent involvement of NK cells.</s><s>To date, the role of NK cells in the pathogenesis of lung fibrosis remains unclear, and their involvement in this process in the context of autoimmune diseases, including aSS, is not known.</s><s>Some studies have reported reduced NK cell function in diseases leading to idiopathic pulmonary fibrosis, through the lack of interactions of NK cells with epithelial cells or collagenproducing cells <ref type="bibr" target="#b33">(34,</ref><ref type="bibr" target="#b34">35)</ref>.</s><s>Some animal models also suggested that NK cells could prevent lung fibrosis, through the production of IFN-g <ref type="bibr" target="#b35">(36)</ref>.</s><s>Our results are consistent with these data, showing a dramatically impaired IFN-g production in aSS patients, which is at least in part due to a lower expression of NKp30.</s></p><p><s>With regard to our blood and tissue compartment results, we suggest that NK cells could be implicated in the aSS pathogenesis.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc><div><p><s>FIGURE 1. Quantitative and phenotypic characteristics of NK cells from aSS patients.</s><s>(A) Percentage and absolute count of blood CD3 2 CD56 + NK cells within the CD45 + lymphocyte gate.</s><s>(B) Percentage of CD56 bright NK cells among blood CD3 2 CD56 + NK cells.</s><s>(C) Percentage of CD3 2 CD56 + NK cells expressing different surface markers among the blood NK cells.</s><s>Data from 26 healthy donors (open boxes), 20 inactive aSS patients (gray boxes), and 13 active aSS patients (black boxes) are shown as a box plot (25th-75th percentiles).</s><s>Lines outside the boxes represent the minimum and maximum values, and lines inside the boxes represent the median value.</s><s>*p , 0.05, **p , 0.01.</s><s>(D) Correlation between NKp30 and CD57 or ILT2 expression on CD3 2 CD56 + NK cells from aSS patients.d,</s><s>Active aSS patients; s, inactive aSS patients.</s><s>(E) ROC curve representing the sensitivity and the specificity of a test (combining the NKp30, CD57, and ILT2 values) in predicting disease activity.</s></p></div></figDesc><graphic coords="5,77.93,58.05,442.94,559.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc><div><p><s>FIGURE 2. NK cell functionality.</s><s>(A) Representative profile of NK cell functions by flow cytometry after a 5-h polyfunctional assay in the presence of K562 target cells (at a 1:1 E:T ratio).</s><s>NK cell degranulation (CD107a) and intracellular production of IFN-g and TNF-a were measured by gating on CD3 2 CD56 + NK cells.</s><s>(B) Degranulation and intracellular cytokine production in NK cells from freshly isolated PBMCs, either nonstimulated (left panel) or stimulated overnight (right panel) by IL-12 plus IL-18.</s><s>Data from 10 controls (open boxes), 10 inactive patients (gray boxes), and 10 active aSS patients (black boxes) are shown as a box plot (25th-75th percentiles).</s><s>Outside lines represent minimum and maximum values, and inside lines represent the median value.</s><s>(C) Polyfunctional assays of resting or IL-12 plus IL-18-stimulating NK cells from 10 controls, 10 inactive patients, and 10 active aSS patients were tested against K562 target cells.</s><s>The mean values were analyzed with a Boolean gate algorithm (FlowJo; Tree Star).</s><s>Pie and arc charts were generated using SPICE software (National Institute of Allergy and Infectious Diseases freeware).</s><s>Pies represent the frequency of NK cells positive for up to three responses (to CD107a, IFN-g, and TNF-a).</s><s>Arcs depict the frequency of positive cells for CD107a, IFN-g, and TNF-a.</s><s>The proportion of NK cells performing three functions was compared between groups.</s><s>*p , 0.05, **p , 0.01, ***p , 0.001.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 3 .</head><label>3</label><figDesc><div><p><s>FIGURE 3. Functional correlations with NKp30.</s><s>(A) Significant correlations between NKp30 and the NK cell functions, that is, degranulation (CD107a) and cytokine production in different experimental conditions, are shown.</s><s>(B) Principal component analysis graphically shows the statistical proximity between the different variables that were tested, as well as the distribution of the patients according to the differential expression of these variables.</s><s>d, Active aSS patients; s, inactive aSS patients.</s><s>(C) Polyfunctional assays of resting or IL-12 plus IL-18-stimulated NK cells from four controls and five aSS patients were tested against P815 target cells in the presence of activating anti-NKp30 Abs (R&amp;D Systems).</s><s>Data were analyzed with Boolean gate algorithm (FlowJo; Tree Star).</s><s>Pie and arc charts were generated using SPICE software (National Institute of Allergy and Infectious Diseases freeware).</s><s>Pies represent the frequency of NK cells positive for up to three responses (to CD107a, IFN-g, and TNF-a).</s><s>Arcs depict the frequency of positive cells for CD107a, IFN-g, and TNF-a.</s><s>The proportion of NK cells performing two or more functions was compared between groups.</s><s>*p , 0.05.</s></p></div></figDesc><graphic coords="7,113.21,390.57,93.59,97.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 4 .</head><label>4</label><figDesc><div><p><s>FIGURE 4. Modulation of NKp30 expression in aSS patients.</s><s>(A) Relative NKp30 mRNA quantification in sorted CD3 -CD56 + NK cells from patients (according to the cell surface NKp30 expression) and healthy controls.</s><s>(B) Examples of cell surface (Mb) and intracellular (IC) expression of NKp30 by flow cytometry stainings.</s><s>(C) Percentages of cell surface (Mb) and intracellular (IC) NKp30 + NK cells in controls, active patients, and inactive aSS patients.</s><s>(D) Percentage of cell-surface NKp30+NK cells after 12-h cultures with medium alone or treated with purified IgG from anti-Jo-1 + patient sera (Jo-1 Ab) or purified IgG from controls (HD IgG).</s><s>Experiments were performed in three controls, five inactive patients, and two active aSS patients.</s><s>(E) Polyfunctional assays of resting or anti-Jo-1-stimulated NK cells from three controls, five inactive patients, and two active aSS patients.</s><s>Assays were performed in the presence of K562 target cells.</s><s>The mean values were analyzed with a Boolean gate algorithm (FlowJo; Tree Star).</s><s>Pie and arc charts were generated using SPICE software (National Institute of Allergy and Infectious Diseases freeware).</s><s>Pies represent the frequency of NK cells positive for up to three responses (to CD107a, IFN-g, and TNF-a).</s><s>Arcs depict the frequency of positive cells for CD107a, IFN-g, and TNF-a.</s><s>None of the results was statistically significant.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIGURE 5 .</head><label>5</label><figDesc><div><p><s>FIGURE 5. NK cell immunohistochemistry stainings in the lung.</s><s>(A) Lung section: NKp46 staining (clone 195314; R&amp;D Systems ) in a normal lung (H&amp;E-stained section).</s><s>(B-D) Lung sections: NKp46 staining in three patients with aSS (H&amp;E-stained section) showing usual interstitial pneumonia with intense fibrosis.</s><s>The distribution of NKp46 + NK cells is dense and diffuse.</s><s>(E) NK cell count/mm 2 in three aSS patients (n = 3) and three healthy controls lung sections showing a dramatic increase density of NK cells in aSS patients.</s><s>Each filled circle represents the patient NK cell count/mm 2 , and the open circle represents the count of the control subject.</s><s>(F) Lung sections (patients 2 and 3): examples of NKp46 + (red) and granzyme B + (Dako, Clone GrB-7) double staining (blue granulations).</s><s>Original magnification is noted in the lower right-hand corner of each panel.</s></p></div></figDesc><graphic coords="10,51.77,67.77,480.38,516.50" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table I .</head><label>I</label><figDesc><div><p><s>Patient characteristics and treatments</s></p></div></figDesc><table><row><cell>Patient</cell><cell>Age (y)</cell><cell>Gender</cell><cell>ARS</cell><cell>Other Autoantibodies</cell><cell>Disease Activity</cell><cell>Treatments</cell></row><row><cell>1</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>MMF, steroids (15 mg)</cell></row><row><cell>2</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Sm</cell><cell>No</cell><cell>AZA, steroids (5 mg)</cell></row><row><cell>3</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>MTX, steroids (5 mg)</cell></row><row><cell>4</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>HCQ</cell></row><row><cell>5</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell>Ro/SSA-52</cell><cell>No</cell><cell>MTX, IV Ig, steroids (5 mg)</cell></row><row><cell>6</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>HCQ, MMF, steroids (15 mg)</cell></row><row><cell>7</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell>Ro/SSA-52</cell><cell>No</cell><cell>Steroids (5 mg)</cell></row><row><cell>8</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell>Not determined</cell><cell>No</cell><cell>Steroids (10 mg)</cell></row><row><cell>9</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>None</cell></row><row><cell>10</cell><cell></cell><cell>F</cell><cell>OJ</cell><cell>Ro/SSA-60, La/SSB</cell><cell>No</cell><cell>Steroids (5 mg)</cell></row><row><cell>11</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>MTX, steroids (8 mg)</cell></row><row><cell>12</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>MTX, IV Ig, steroids (25 mg)</cell></row><row><cell>13</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell>Ro/SSA-52, DNA a</cell><cell>No</cell><cell>MMF, steroids (6 mg)</cell></row><row><cell>14</cell><cell></cell><cell>F</cell><cell>EJ</cell><cell></cell><cell>No</cell><cell>None</cell></row><row><cell>15</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell>RNP, Ro/SSA-52, Ro/SSA-60</cell><cell>No</cell><cell>MMF, steroids (10 mg)</cell></row><row><cell>16</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>None</cell></row><row><cell>17</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-60</cell><cell>No</cell><cell>HCQ, MTX, steroids (6 mg)</cell></row><row><cell>18</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell></cell><cell>No</cell><cell>MTX, steroids (7 mg)</cell></row><row><cell>19</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-52, Ro/SSA-60</cell><cell>No</cell><cell>MTX, steroids (5 mg)</cell></row><row><cell>20</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-60</cell><cell>No</cell><cell>MTX, steroids (8 mg)</cell></row><row><cell>21</cell><cell></cell><cell>F</cell><cell>PL7</cell><cell>Ro/SSA-60</cell><cell>Yes, muscle</cell><cell>HCQ, steroids (10 mg)</cell></row><row><cell>22</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-52</cell><cell>Yes, ILD</cell><cell>MMF, steroids (10 mg)</cell></row><row><cell>23</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle</cell><cell>Steroids (20 mg)</cell></row><row><cell>24</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>Yes, muscle</cell><cell>None</cell></row><row><cell>25</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell></cell><cell>Yes, muscle</cell><cell>None</cell></row><row><cell>26</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle</cell><cell>MMF, steroids (15 mg)</cell></row><row><cell>27</cell><cell></cell><cell>F</cell><cell>PL12</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle and ILD</cell><cell>None</cell></row><row><cell>28</cell><cell></cell><cell>F</cell><cell>PL7</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle and joints</cell><cell>Steroids (7 mg)</cell></row><row><cell>29</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle</cell><cell>MMF, steroids (20 mg)</cell></row><row><cell>30</cell><cell></cell><cell>F</cell><cell>PL7</cell><cell>Ro/SSA-52</cell><cell>Yes, muscle</cell><cell>None</cell></row><row><cell>31</cell><cell></cell><cell>M</cell><cell>Jo-1</cell><cell></cell><cell>Yes, muscle</cell><cell>MTX, steroids (15 mg)</cell></row><row><cell>32</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>Yes, muscle and joints</cell><cell>None</cell></row><row><cell>33</cell><cell></cell><cell>F</cell><cell>Jo-1</cell><cell></cell><cell>Yes, ILD, joints, and skin</cell><cell>None</cell></row></table><note><p><s>ARS, anti-tRNA synthetase Ab (12 mg), daily dose of steroids (mg); AZA, azathioprine; HCQ, hydroxychloroquine; IV Ig, i.v.Igs; MMF, mycophenolate mofetil; MTX, methotrexate.a</s><s>By Luminex/FIDIS technique.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">by guest on May 17, 2022 http://www.jimmunol.org/ Downloaded from</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Further work is however needed to determine the exact role of NK cells within the tissue.</s><s>Additionally, our data also suggest a possible involvement of the NKp30 pathway in the development and/or progression of aSS.</s><s>Whether NKp30 could be used as a biomarker predictive of aSS outcome and whether this pathway could be drug targetable also remain to be determined.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosures</head><p><s>The authors have no financial conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical heterogeneity and outcomes of antisynthetase syndrome</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Rheumatol. Rep</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">349</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Devilliers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stanciu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Uzunhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Masseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dubucquoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P.-Y</forename><surname>Hatron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Musset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wallaert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autoimmun. Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="210" to="217" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Aggarwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fertig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Koontz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Ascherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann. Rheum. Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="227" to="232" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dieval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Uzunhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Devilliers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Canuet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Te ˆtu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Agard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sibilia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. Respir. J</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1271" to="1282" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stanciu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guiguet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Musset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Touitou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Beigelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rigolet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Costedoat-Chalumeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Allenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dubourg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1835" to="1839" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Askin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tuder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mullins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Casciola-Rosen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="2729" to="2739" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">M Z</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Casciola-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ha ¨rtlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="781" to="791" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Harlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Liu-Bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Ridgway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Clemens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Ascherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="1865" to="1872" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Innate or adaptive immunity? The example of natural killer cells</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Raulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Caligiuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zitvogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Lanier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ugolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">331</biblScope>
			<biblScope unit="page" from="44" to="49" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The biology of human natural killer-cell subsets</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fehniger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Caligiuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Immunol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="633" to="640" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Nune `s. 2013. ADAPted secretion of cytokines in NK cells</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ugolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1108" to="1110" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">CMV drives clonal expansion of NKG2C + NK cells expressing self-specific KIRs in chronic hepatitis patients</title>
		<author>
			<persName><forename type="first">V</forename><surname>Be ´ziat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dalgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Asselah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Halfon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bedossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boudifa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Theodorou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martinot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Debre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="447" to="457" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">NCR3/NKp30 contributes to pathogenesis in primary Sjo ¨gren&apos;s syndrome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rusakiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nocturne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lazure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Semeraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Flament</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Caillat-Zucman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Se `ne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Delahaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chaba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="195" to="196" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-g production in patients with active disease</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hervier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Beziat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Haroche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mathian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lebon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ghillani-Dalbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Musset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Debre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Amoura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vieillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1698" to="1706" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cherfils-Vicini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Platonova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Laurans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Validire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caliandro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Magdeleinat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mami-Chouaib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-C</forename><surname>Dieu-Nosjean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W.-H</forename><surname>Fridman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1285" to="1297" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile</title>
		<author>
			<persName><forename type="first">C</forename><surname>Preuße</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Goebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Held</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wengert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Scheibe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Irlbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Heppner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Stenzel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Pathol</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="2161" to="2171" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">N</forename><surname>Schleinitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cognet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laugier-Anfossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baratin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pouget</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-F</forename><surname>Pelissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-R</forename><surname>Harle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="3216" to="3223" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures</title>
		<author>
			<persName><forename type="first">M.-C</forename><surname>Dieu-Nosjean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Antoine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Danel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Heudes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wislez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Poulot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rabbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Laurans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tartour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Chaisemartin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="4410" to="4417" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CD56 bright CD16 + NK cells: a functional intermediate stage of NK cell differentiation</title>
		<author>
			<persName><forename type="first">V</forename><surname>Be ´ziat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Duffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Quoc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Le</forename><surname>Garff-Tavernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Decocq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Combadie `re</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Debre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vieillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="6753" to="6761" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">CD62L expression identifies a unique subset of polyfunctional CD56 dim NK cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Juelke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Killig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Luetke-Eversloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Parente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gruen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Morandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ferlazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schmitt-Knosalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Romagnani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="1299" to="1307" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Natural killer cells in human autoimmune disorders</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Fogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>French</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res. Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">216</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in mixed cryoglobulinemia</title>
		<author>
			<persName><forename type="first">I</forename><surname>Puxeddu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bongiorni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chimenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Capecchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Migliorini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Joint Bone Spine</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="107" to="108" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hagberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Theorell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schlums</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-L</forename><surname>Eloranta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Bryceson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="2989" to="2998" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Cell surface expression of activating receptors and coreceptors on peripheral blood NK cells in systemic autoimmune diseases</title>
		<author>
			<persName><forename type="first">I</forename><surname>Puxeddu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bongiorni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chimenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Migliorini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand. J. Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="298" to="304" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Delahaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rusakiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Me ´nard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lyonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sarabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chaput</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Semeraro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="700" to="707" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pende</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Castriconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Romagnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Spaggiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marcenaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dondero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lazzeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lasagni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Martini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rivera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="2030" to="2036" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ferlazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Paludan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Strowig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bougras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>M€</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="s">Proc. Natl. Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="16606" to="16611" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">NK-dependent DC maturation is mediated by TNFa and IFNa released upon engagement of the NKp30 triggering receptor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Della</forename><surname>Chiesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carlomagno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pende</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">`</forename></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moretta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="566" to="571" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Naturalkiller cells and dendritic cells: &quot;l&apos;union fait la force</title>
		<author>
			<persName><forename type="first">T</forename><surname>Walzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zitvogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vivier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="2252" to="2258" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect</title>
		<author>
			<persName><forename type="first">S</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dhedin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-P</forename><surname>Vernant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jijakli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rouas-Freiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Carosella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boudifa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Debre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vieillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="4135" to="4142" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chiossone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Morreale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lanino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cottalasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moretti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Mingari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="455" to="460" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Signatures of human NK cell development and terminal differentiation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Luetke-Eversloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Killig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Romagnani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">499</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fertig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Katsumata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Domsic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Ascherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="3125" to="3131" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cigarette smoke impairs NK cell-dependent tumor immune surveillance</title>
		<author>
			<persName><forename type="first">L.-M</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C J</forename><surname>Zavitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kianpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Sta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="936" to="943" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aquino-Galvez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pe ´rez-Rodrı ´guez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Camarena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Falfan-Valencia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montan ˜o</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Barrera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sada-Ovalle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramı ´rez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Granados</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="639" to="648" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Regulation of pulmonary fibrosis by chemokine receptor CXCR3</title>
		<author>
			<persName><forename type="first">D</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hodge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Homer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="291" to="299" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
